NAVB - Navidea Biopharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue1,169.3511,810.4374,971.6343,013.361
Cost of Revenue96.6363.65162.263.226
Gross Profit1,072.7151,806.7864,909.3743,010.135
Operating Expenses
Research Development4,221.8814,513.8427,138.0810,562.729
Selling General and Administrative6,598.13510,691.9517,920.03610,888.146
Non Recurring----
Others----
Total Operating Expenses10,916.65215,209.44415,120.37621,454.101
Operating Income or Loss-9,747.301-13,399.007-10,148.742-18,440.74
Income from Continuing Operations
Total Other Income/Expenses Net-6,421.27-4,390.6792,770.848-4,603.857
Earnings Before Interest and Taxes-9,747.301-13,399.007-10,148.742-18,440.74
Interest Expense-161.799-159.029-4.866-1,269.916
Income Before Tax-16,168.571-17,789.686-7,377.894-23,044.597
Income Tax Expense-9.753-4,062.489--
Minority Interest668.321668.7468.91469.558
Net Income From Continuing Ops-16,158.818-13,727.197-7,377.894-23,044.597
Non-recurring Events
Discontinued Operations44.50288,673.053-6,931.137-4,518.938
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-16,113.93774,946.066-14,308.383-27,562.68
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-16,113.93774,946.066-14,308.383-27,608.68